Multiple Sclerosis
Conference Coverage
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
SAN DIEGO—Patients with relapsing-remitting multiple sclerosis (MS) who received high doses of the novel human endogenous retrovirus-W antagonist...
Conference Coverage
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
SAN DIEGO—The monoclonal antibody alemtuzumab can be an effective treatment for people living with multiple sclerosis (MS), but the agent is also...
Conference Coverage
Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
SAN DIEGO—Patients with multiple sclerosis (MS) who are treated by primary care physicians are significantly less likely to receive disease-...
Conference Coverage
Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
SAN DIEGO—Among patients with multiple sclerosis (MS) who are positive for the John Cunningham virus (JCV), extended-interval dosing of...
Conference Coverage
MicroRNA Could Be a Biomarker of MS
SAN DIEGO—Absence of miR-219, a microRNA (miRNA), in CSF could be a biomarker of multiple sclerosis (MS), according to data presented at the...
Conference Coverage
Clean-Surfaced Nanocrystalline Gold May Promote Remyelination
SAN DIEGO—A novel therapy designed to promote the maturation and activation of myelin-producing oligodendrocytes is moving to phase II clinical...
Literature Review
Natalizumab May Be Associated With Increased Disease Activity During Pregnancy
Women with relapsing-remitting multiple sclerosis (MS) who discontinue natalizumab treatment before pregnancy may have increased disease activity...
Literature Review
Are Complementary and Alternative Treatments Effective for MS?
Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...
From the Journals
Frankincense extract may reduce disease activity in relapsing-remitting MS
Safety results and potential efficacy point to possible future clinical development.
From the Journals
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
But the absolute difference in the rate of confirmed disability progression versus placebo was small.
From the Journals
MRI finds PML in some natalizumab-treated patients despite negative CSF, no symptoms
Correlation also observed between viral load and lesion volume.